Stem Cell Clinic

Global Wearable Artificial Organs Market Is Expected to Reach USD 17.48 billion by 2027 : Fior Markets – GlobeNewswire

By adminSeptember 10, 2020Stell Cell Research

September 08, 2020 08:02 ET | Source: Fior Markets

Newark, NJ, Sept. 08, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, theglobal wearable artificial organs market is expected to grow from USD 5.26 billion in 2019 and to reach USD 17.48 billion by 2027, growing at a CAGR of 16.20% during the forecast period 2020-2027.

The rising demand and supply gap of organ donors, along with the increasing frequency of organ failure, is driving the market growth. Technological advancement and continuous investments in research and development activities for wearable artificial organs also boost the market growth. The artificial organ is an engineered tool integrated into human living tissues to substitute the human organ. The requirement for wearable artificial organs is increasing due to less cost of wearable artificial organs than organ transplantation and the growing number of geriatric populations prone to kidney failure. Leading players in the industry are emphasizing on the advancement of wearable artificial organs for the disease that cannot be cured with alternative techniques. Wearable and portable devices would potentially enhance the quality of life by enabling patients to continue their daily activities while undergoing therapy or dialysis. Improvement in the field of stem cell, microelectronics, nanotechnology, artificial intelligence, genetic engineering, genomics, proteomics, and bioinformatics is generating new avenues for wearable artificial organs.

Artificial organs are synthetic machines or devices that replace several human organs that undergo from the malfunctioning or loss of complete functioning ability. Artificial organs are constructed from human stem cells and then developed in laboratories. However, advancements and innovation of modern artificial organs are still improving, offering significant growth outlooks to the global artificial organs market during the forecast period. An artificial organ is an engineered tissue or tool that is implanted into the human body. The artificial organs replace a natural organ to replicate a distinct function so that the patient can return to a healthy life. It is a remedial tool with a biochemical or mechanical function such as lung, heart, liver, kidney, or neurosensory organs.

Producers in the industry are focused on organ repair and biological replacement that will operate as a tissue-based artificial organ and simulates a physiological function of an organ. The devices are customized to the changing needs of the patients. The market for wearable artificial organs is shifting from mechanical alternative towards original biological replacement. Moreover, the machines are less expensive than organ transplants, thereby generating new opportunities and demand in the market. Improving healthcare infrastructure and decreasing waiting time for FDA permission are also factors that augment market growth. For instance, in August 2019, FDA authorized MED-EL Cochlear Implant System for asymmetric hearing loss. The system is utilized for children five years and older. A high number of permanent injuries, as well as rising incidence of road accidence, are also creating demand for wearable artificial organs.

DOWNLOAD FREE SAMPLE REPORT AThttps://www.fiormarkets.com/report-detail/418835/request-sample

Key players operating in the global wearable artificial organs market include Medtronic, AWAK Technology, Second Sight Medical Products, Inc., Cochlear Ltd., Ekso bionics, MED-EL, Abbott Laboratories, Boston Scientific, HDT Global, Touch Bionics, Inc., Neurotron Biotechnology, Retina Implant AG, ReWalk Robotics, Rex Bionics Plc., Suit X (U.S. Bionics Inc.) and Lockheed Martin Corporation. To gain a significant market share in the global wearable artificial organs market, the key players are now focusing on adopting strategies such as product innovations, mergers & acquisitions, recent developments, joint ventures, collaborations, and partnerships.

The cochlear implant segment dominated the market and held the largest market share of 19.07% in the year 2019 The product segment includes vision bionics, brain bionics, bionic limbs, exoskeleton, cochlear implants, pancreas and kidney. The cochlear implants segment held the highest share of 19.07% in the wearable artificial organs market in 2019 due to frequent product launches. In December 2019, the FDA authorized the first active Osseointegrated steady-state implant, which can be utilized for children of 12 years and older with single-sided sensorineural deafness. The device would help in enhancing the patients capacity to hear in both quiet and noisy situations.

The electronic segment dominated the market and valued at USD 2.85 billion in the year 2019 The technology segment includes electronic and mechanical. The electronic segment held the highest share of UDS 2.85 billion in the wearable artificial organs market in 2019. It is due to the rising adoption of electronic wearable artificial organs and technological advancement. The need for electronic wearable artificial organs among amputees is rising. Electronic and battery systems are utilized to generate muscle and nerve movement in the remaining organ. The devices are creating a revolution in the therapeutic electronics industry. The market is anticipated to observe innovative product launches over the forecast period. For instance, in June 2020, Medtronic exhibited the positive results of MiniMed 780G System, its artificial pancreas. The device would give both basal insulin and correction boluses every five minutes to serve patients to avoid high and lows of insulin with greater comfort.

Browse full report with TOC athttps://www.fiormarkets.com/report/wearable-artificial-organs-market-by-product-vision-bionics-418835.html

Regional Segment Analysis of Global Wearable Artificial Organs Market

On the basis of geography, the global wearable artificial organs market is classified into North America, Europe, South America, Asia Pacific, and Middle East and Africa. North America had the largest share of 26.38% in the wearable artificial organs market in 2019. Rising research and development investment and speedy FDA permissions of the wearable artificial organs boost the demand in the region. The presence of significant market players and extremely modern healthcare infrastructure is also increasing the application in the region. In North America, the U.S. dominated the market due to factors such as favorable reimbursement policies, large patient pool, and deepening shortage of organ donors.

Request for Customization:https://www.fiormarkets.com/enquiry/request-customization/418835

About the report: The global wearable artificial organs market is analyzed on the basis of value (USD Billion), export (K Units), and import (K Units). All the segments have been analyzed on global, regional and country basis. The study includes an analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porters five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.

For Instant Purchase:https://www.fiormarkets.com/checkout.html?reportid=418835&type=single

Customization of the Report:

The report can be customized as per client requirements. For further queries, you can contact us onsales@fiormarkets.comor +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

About Fior Markets

Fior Markets is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports. Fior Markets deploys a wide range of regional and global market intelligence research reports including industries like technology, pharmaceutical, consumer goods, food and beverages, chemicals, media, materials and many others. Our Strategic Intelligence capabilities are purposely planned to boost your business extension and elucidate the vigor of diverse industry. We hold distinguished units of highly expert analysts and consultants according to their respective domains. The global market research reports we provide involve both qualitative and quantitative analysis of current market scenario as per the geographical regions segregated and comprehensive performance in different regions with global approach. In addition, our syndicated research reports offer a packaged guide to keep companies abreast of the upcoming major restyle in their domains. Fior Markets facilitates clients with research analysis that are customized to their exact requirements, specifications and challenges, whether it is comprehensive desk research, survey work, composition of multiple methods, in-detailed interviewing or competitive intelligence. Our research experts are experienced in matching the exact personnel and methodology to your business need.

Avinash D Head of Business Development Phone:+1-201-465-4211 Email:sales@fiormarkets.com Web:www.fiormarkets.com

To Read Top Industries Reports, Visit our Affiliated Website: https://researchstore.biz/

Related Reports Enteral Feeding Devices Market - https://www.fiormarkets.com/report/enteral-feeding-devices-market-by-type-enteral-feeding-418637.html Insulin Storage Devices Market - https://www.fiormarkets.com/report/insulin-storage-devices-market-by-type-insulated-kits-418526.html Healthcare Analytical Testing Services Market - https://www.fiormarkets.com/report/healthcare-analytical-testing-services-market-by-type-stability-418517.html Extracorporeal Membrane Oxygenation (ECMO) Market - https://www.fiormarkets.com/report/extracorporeal-membrane-oxygenation-ecmo-market-by-component-accessories-418492.html

View post:
Global Wearable Artificial Organs Market Is Expected to Reach USD 17.48 billion by 2027 : Fior Markets - GlobeNewswire

Global Organoids and Spheroids Market Is Expected to Reach USD 2794.79 Million by 2027 : Fior Markets – Yahoo Finance

By adminSeptember 10, 2020Stell Cell Research

Organoids and Spheroids Market by Type (Organoids and Spheroids), Application (Personalized Medicine, Developmental Biology, Drug Toxicity and Efficacy Testing, Disease Pathology Testing and Regenerative Medicine), End-Use, Region, Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast 2020 to 2027

Newark, NJ, Sept. 08, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, the global organoids and spheroids market is expected to grow from USD 502.92 million in 2019 and to reach USD 2794.79 million by 2027, growing at a CAGR of 23.91 % during the forecast period 2020-2027.

The growing prevalence of chronic disorders in recent times has increased the demand for effective drugs. The organoids and spheroids model is increasingly becoming popular as they provide a better perspective for human developmental biology research. The organoids model reveals the effects of covid-19 on several intestinal cells. Thus, these models are playing a significant role in the vaccine development process. The rise in demand for diagnostics and therapeutics solutions for these chronic diseases is fuelling market growth.

The organoids and spheroids are the three-dimensional structures that replicate the condition of different tissues present in the human body. The organoids model works as an in-vitro model for the study of biological development. The organoids can be established for organs such as kidney, retina, brain, liver, small and large intestine, lungs, etc. The organoids can be derived from a single adult stem cell or the embryonic stem cell. On the other hand, spheroids consist of a cluster of cells. These are derived from both the single-cell type and multi-cellular stems. The organoids and spheroids differ in the driving force required for the development. The organoids are formed by internal development processes and spheroids forms by adhesion of cells to each other. These also differ in the time duration for which the 3D culture can be maintained.

The human organoids have helped in the analysis of many tissues, which helps in a better understanding of the working of the organs. The 3D models of human organs have opened up opportunities for conducting various studies and experiments to analyze the effects of drugs on different organs. It also has provided potential ways of organ transplantation. Further, the growing technological advancements in the spheroid and organoid 3D models are fuelling the market growth. Apart from this, the major players operating in the market are also focusing on facilitating cell activities by taking control of the microenvironment of the culture.

DOWNLOAD FREE SAMPLE REPORT AThttps://www.fiormarkets.com/report-detail/418832/request-sample

Key players operating in the organoids and spheroids market are 3D Biotek LLC, 3D Biomatrix, ATCC, Cellesce Ltd., Hubrecht Organoid Technology (HUB), Merck KGaA, STEMCELL Technologies Inc., Corning Incorporated, AMS Biotechnology Limited, Perkin Elmer, Kuraray, Thermo Fisher Scientific, Inc., Greiner Bio-One, Prellis Biologics, Lonza and others. The major players in the organoids and spheroids market are focusing on expansionary strategies such as mergers & acquisitions, recent developments, joint ventures, collaborations, product innovations and partnerships. These strategies would extract higher market shares for the players and thus strengthen their position in the global market. Thermo Fisher Scientific and Corning Incorporated are some of the biggest manufacturers and suppliers of organoids and spheroids in the global market.

Spheroids segment dominated the market and held the largest market share of 54.92% in the year 2019

On the basis of type segment, the global organoids and spheroids market includes organoids and spheroids. The organoids are segmented into product type, techniques and source. The product type of organoids includes neural organoids, intestinal organoids, hepatic organoids and others. The techniques include crypt organoid culture techniques, general submerged technique, clonal organoid from Lgr5+ cells, air-liquid interface (ALI) method and brain and retina organoid formation protocol. The sources segment includes primary tissues and stem cells. The spheroids are also segmented into product type, techniques and source. The product type of spheroids includes mammospheres, neurospheres, embryoid bodies, multi-cellular tumor spheroids and hepatospheres. The techniques segment includes hanging drop method, micropatterned plates, low cell attachment plates and others. The source of spheroid includes primary cells, cell line and iPSCs derived cells. Spheroids dominated the market and held the largest market share of 54.92% in the year 2019. The spheroids are in high demand owing to its increased application in cancer research and drug discovery. The spheroids can be cultured to produce cells of consistent shape, which can be used for thorough analysis. Further, the organoids segment is projected to register an impressive growth rate as these are used as in-vitro models in the process of drug discovery. The segment is expected to be driven by the intestinal organoids type owing to the increased application is cell biology and disease modeling.

Story continues

Developmental biology segment dominated the market and held the largest market share of 28.65% in the year 2019

On the basis of the application segment, the global organoids and spheroids market includes personalized medicine, developmental biology, drug toxicity and efficacy testing, disease pathology testing and regenerative medicine. Developmental biology dominated the market and held the largest market share of 28.65% in the year 2019. The organoids which are derived from induced pluripotent stem cells and embryonic stem cells are useful in human developmental biology. The spheroids and organoids have been increasingly used in the development biology study of the pancreas, kidney, stomach, liver, etc. for the purpose of embryonic development, tissue homeostasis and lineage specification.

Biotechnology and pharmaceutical companies segment dominated the market and held the largest market share of 39.82% in the year 2019

The end-user segment includes academic and research institutes, hospitals and diagnostic centers and biotechnology and pharmaceutical companies. Biotechnology and pharmaceutical companies segment dominated the market and held the largest market share of 39.82% in the year 2019. The organoids and spheroids are mainly used in clinical applications owing to the vast scope of the experiment. Thus, the biotechnology and pharmaceutical companies are using these increasingly in the drug discovery processes.

Browse full report with TOC athttps://www.fiormarkets.com/report/organoids-and-spheroids-market-by-type-organoids-and-418832.html

Regional Segment Analysis of the Organoids and Spheroids Market

On the basis of geography, the global organoids and spheroids market is classified into North America, Europe, South America, Asia Pacific, and the Middle East and Africa. North America region accounted for a significant market share of 43.02% in the year 2019. The region has been lately, investing in the organoid and spheroids based research models. Further, the growing technological advancements provides a platform for extensive research on 3D models of human tissue structure for the development of personalized and regenerative medicines. However, Asia-Pacific is expected to register the highest growth rate during the forecast period. The growing patient population owing to the prevalence of chronic diseases has led to the development of the market in the region. Further, the growth of stem cell research has increased the demand for organoids and spheroids.

Request for Customization:https://www.fiormarkets.com/enquiry/request-customization/418832

About the report:

The global organoids and spheroids market is analyzed on the basis of value (USD Million). All the segments have been analyzed on global, regional and country basis. The study includes an analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter's five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.

For Instant Purchase:https://www.fiormarkets.com/checkout.html?reportid=418832&type=single

Customization of the Report:

About Fior Markets

Avinash D Head of Business Development Phone:+1-201-465-4211 Email:sales@fiormarkets.com Web:www.fiormarkets.com

To Read Top Industries Reports, Visit our Affiliated Website: https://www.marketquest.biz

Original post:
Global Organoids and Spheroids Market Is Expected to Reach USD 2794.79 Million by 2027 : Fior Markets - Yahoo Finance

Competitive Scenario of Animal Stem Cell Therapy Market Growth, Size, Demand, Forecast with Depth Assessment by Top Key Players 2025 – Scientect

By adminSeptember 10, 2020Stell Cell Research

Key Questions Answered in The Report:

Purchase this report (Price With the slowdown in world economic growth, the Animal Stem Cell Therapy industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Animal Stem Cell Therapy market size to maintain the average annual growth rate of 0.148698354997 from 8.0 million USD in 2014 to 16.0 million USD in 2019, Report analysts believe that in the next few years, Animal Stem Cell Therapy market size will be further expanded, we expect that by 2024, The market size of the Animal Stem Cell Therapy will reach 80.0 million USD. USD for single user license)https://www.360researchreports.com/purchase/15079719

Major Highlights of TOC:

1 Report Overview

1.1 Study Scope

1.2 Key Market Segments

1.3 Regulatory Scenario by Region/Country

1.4 Market Investment Scenario Strategic

1.5 Market Analysis by Type

1.5.1 Global Animal Stem Cell Therapy Market Share by Type (2020-2026)

1.6 Market by Application

1.6.1 Global Animal Stem Cell Therapy Market Share by Application (2020-2026)

2.Global Market Growth Trends

2.1 Industry Trends

2.1.1 SWOT Analysis

2.1.2 Porters Five Forces Analysis

2.2 Potential Market and Growth Potential Analysis

2.3 Industry News and Policies by Regions

2.3.1 Industry News

2.3.2 Industry Policies

3 Value Chain of Animal Stem Cell Therapy Market

3.1 Value Chain Status

3.2 Animal Stem Cell Therapy Manufacturing Cost Structure Analysis

3.2.1 Production Process Analysis

3.2.2 Manufacturing Cost Structure of Electric Cookers

3.2.3 Labor Cost of Electric Cookers

4 Players Profiles

4.1 Media

4.1.1 Medea Basic Information

4.1.2 Animal Stem Cell Therapy Product Profiles, Application and Specification

4.1.3 Medea Animal Stem Cell Therapy Market Performance (2015-2020)

4.1.4 Medea Business Overview

5 Global Animal Stem Cell Therapy Market Analysis by Regions

5.1 Global Animal Stem Cell Therapy Sales, Revenue and Market Share by Regions

5.1.1 Global Animal Stem Cell Therapy Sales by Regions (2015-2020)

5.1.2 Global Animal Stem Cell Therapy Revenue by Regions (2015-2020)

5.2 North America Animal Stem Cell Therapy Sales and Growth Rate (2015-2020)

5.3 Europe Animal Stem Cell Therapy Sales and Growth Rate (2015-2020)

5.4 Asia-Pacific Animal Stem Cell Therapy Sales and Growth Rate (2015-2020)

Request for Customization @ https://www.360researchreports.com/TOC/15079719#TOC

6 North America Animal Stem Cell Therapy Market Analysis by Countries

6.1 North America Animal Stem Cell Therapy Sales, Revenue and Market Share by Countries

6.1.1 North America Animal Stem Cell Therapy Sales by Countries (2015-2020)

6.1.2 North America Animal Stem Cell Therapy Revenue by Countries (2015-2020)

6.2 United States Animal Stem Cell Therapy Sales and Growth Rate (2015-2020)

7 Europe Animal Stem Cell Therapy Market Analysis by Countries

7.1 Europe Animal Stem Cell Therapy Sales, Revenue and Market Share by Countries

7.1.1 Europe Animal Stem Cell Therapy Sales by Countries (2015-2020)

7.1.2 Europe Animal Stem Cell Therapy Revenue by Countries (2015-2020)

7.2 Germany Animal Stem Cell Therapy Sales and Growth Rate (2015-2020)

7.3 UK Animal Stem Cell Therapy Sales and Growth Rate (2015-2020)

7.4 France Animal Stem Cell Therapy Sales and Growth Rate (2015-2020)

7.5 Italy Animal Stem Cell Therapy Sales and Growth Rate (2015-2020)

8 Asia-Pacific Animal Stem Cell Therapy Market Analysis by Countries

8.1 Asia-Pacific Animal Stem Cell Therapy Sales, Revenue and Market Share by Countries

8.1.1 Asia-Pacific Animal Stem Cell Therapy Sales by Countries (2015-2020)

8.1.2 Asia-Pacific Animal Stem Cell Therapy Revenue by Countries (2015-2020

8.2 China Animal Stem Cell Therapy Sales and Growth Rate (2015-2020)

8.3 Japan Animal Stem Cell Therapy Sales and Growth Rate (2015-2020)

Continued.

Animal Stem Cell Therapy Market Key Benefits

About Us:

360 Research Reports is the credible source for gaining the market reports that will provide you with the lead your business needs. At 360 Research Reports, our objective is providing a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision makers in finding most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.

Name: Mr. Ajay More

Email: [emailprotected]

Organization: 360 Research Reports

Phone: +44 20 3239 8187/ +14242530807

For More Related Reports Click Here :

Global Amoxycillin Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026

Global Diatom Mud Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026

Europe Sensors Industry Market Research Report

Global Pain Management Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026

Global Histology and Cytology Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026

Originally posted here:
Competitive Scenario of Animal Stem Cell Therapy Market Growth, Size, Demand, Forecast with Depth Assessment by Top Key Players 2025 - Scientect

D&D Pharmatech Announces Launch of Valted Seq Subsidiary Focusing on Discovery of Neurodegenerative Disease Pathways and Biomarkers to Support…

By adminSeptember 10, 2020Stell Cell Research

GYEONGGI-DO, South Korea & GAITHERSBURG, Md.--(BUSINESS WIRE)--D&D Pharmatech, Inc. (D&D), a clinical-stage biotechnology company focused on development and commercialization of revolutionary medicines, today announced the launch of their fourth subsidiary, Valted Seq. D&D Pharmatech is also the parent company of Neuraly, Precision Molecular, and Theraly Fibrosis.

Valted Seq is focused on the discovery of neurodegenerative pathways and biomarkers to inform and accelerate development of new therapeutics and diagnostics, including companion diagnostics which play a critical role in enabling advanced therapeutics. To achieve this, the company has created the worlds largest repository of single-cell sequencing data from high-quality, clinically characterized brain tissues of patients with neurodegenerative diseases including Alzheimers and Parkinsons.

We are excited to be a member of the D&D Pharmatech family of companies and are grateful for their investment which will ultimately improve our ability to diagnose and treat neurodegenerative diseases, said Valina Dawson, Ph.D., Interim Chief Executive Officer of Valted Seq. Valted Seq was founded on the belief that a deeper understanding of neurodegenerative pathways is essential to develop precision therapeutics and identify novel biomarkers to diagnose, guide therapies and monitor some of our most challenging and devastating diseases. We expect this unprecedented repository of single-cell genomics, which Valted Seq will explore using advanced big data analytics, will accelerate progress towards better outcomes for patients. Dr. Dawson is Director of the Neuroregeneration and Stem Cell Programs in the Institute for Cell Engineering at the Johns Hopkins University.

The ongoing collection and comprehensive analysis of thousands of brain tissue samples using Valted Seqs state-of-the-art single-cell analysis technology will support a number of projects including development of a first-in-class liquid biopsy assay for blood-based biomarkers for detection and monitoring of Parkinsons disease. The assay is being developed to be utilized in both internal and external clinical trials for emerging Parkinsons therapies; Valted Seq has already been approached by pharmaceutical companies seeking access to the proprietary biomarker assays. The company continues to expand and has added experienced leaders in bioinformatics and diagnostics to advance the technology through product development and towards commercialization.

We are excited to introduce Valted Seq as one of D&Ds companies, said Dr. Seulki Lee, Chief Executive Officer of D&D Pharmatech. Our subsidiaries, which to date have originated from technologies from leading research institutes, are examples of how D&D and academia have worked in close collaboration to build a powerful engine to accelerate translation of innovation from the academic setting into a framework for commercialization. The launch of Valted Seq exemplifies this successful type of collaboration and represents a model that D&D is extending to other preeminent universities.

In recent years, D&D has invested more than $7 million in sponsored research at leading medical research institutions to advance potentially game-changing healthcare innovations.

By establishing a set of subsidiaries that cover the full spectrum of screening, diagnosis, therapy and therapeutic monitoring of diseases affecting the central nervous system, D&D is creating synergies that would not otherwise be achievable. Three subsidiaries are enabling a comprehensive Total Care approach to neurodegeneration: Valted Seq is identifying novel biomarkers for diagnosing and screening Parkinsons and Alzheimers disease; Precision Molecular is advancing neuromolecular imaging to identify and/or follow patients for therapies being developed by Neuraly and is developing new imaging biomarkers based on Valted Seq discoveries. The academic founders of these subsidiaries remain deeply engaged with each other and industry experts, enabling D&D to create a continuum from groundbreaking science to innovative pipelines.

About D&D Pharmatech

D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty. This corporate structure creates a unique opportunity to accelerate translation of cutting-edge research into lifesaving therapeutic products for patients. The companys product pipeline focuses on a range of indications including neurodegenerative and fibrotic diseases. D&D Pharmatech is the parent company of U.S.-based Neuraly Inc., Theraly Fibrosis Inc., Precision Molecular Inc. and Valted Seq, Inc. For more information, please visit http://www.ddpharmatech.com/

Continued here:
D&D Pharmatech Announces Launch of Valted Seq Subsidiary Focusing on Discovery of Neurodegenerative Disease Pathways and Biomarkers to Support...

Biopreservation Market To Reach USD 5.63 Billion By 2027 | Reports and Data – GlobeNewswire

By adminSeptember 10, 2020Stell Cell Research

September 08, 2020 19:00 ET | Source: Reports and Data

New York, Sept. 08, 2020 (GLOBE NEWSWIRE) -- The globalBiopreservation Market is forecast to reach USD 5.63 Billion by 2027, according to a new report by Reports and Data. A rise in the incidence of chronic diseases, such as renal, cardiac, cancer, and diabetes, will propel the demand for the market.

According to the International Diabetes Federation (IDF), approximately 463 million adults, in 2019, were living with diabetes, and by the year 2045, the number is expected to rise to 700 million. The disease led to 4.2 million deaths and caused the healthcare sector USD 760 billion. Cancer caused almost 9.6 million deaths in 2018. The number of cases is expected to rise to 30 million by 2040 from 18 million in 2018.

Moreover, factors like varying disease patterns, increasing awareness among the population for general wellness and overall healthcare, flexible government policies and regulations together with the applicability of stem cells in research centers focusing on cancer treatment is estimated to escalate the market demand across regions in the upcoming years.

North America dominates the market owing to the increasing number of manufacturers in the region, the spread of infectious diseases, improved healthcare infrastructure, and the development of various new products. Increasing the production of innovative products and the growth of manufacturers in their countries has led Europe to expand its global presence in the industry supported by mergers and acquisitions that are increasing the global presence of European market players.

Get FREE Sample Copy with TOC of the Report to understand the structure of the complete report@ https://www.reportsanddata.com/sample-enquiry-form/3470

The Covid-19 Impact

The market will witness a huge surge as biopharmaceutical innovators are in the front line for the human response to the global COVID-19 pandemic. A significant number of biotech firms are in the middle of the race to investigate the virus's genome and are preparing a viable vaccine. These companies are investigating the virus at an unprecedented rate, and considerable funds are being put into the research. The companies are in trial stage, and the public and private sectors are working continuously for the development of the vaccine. Cash inflow for research in the healthcare sector to find a cure for infectious and autoimmune diseases will aid the market in growth.

Further key findings from the report suggest

To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/biopreservation-market

For the purpose of this report, Reports and Data have segmented into the global Biopreservation market on the basis of the type, biospecimen, application, end-users, and region:

Type Outlook (Revenue, USD Billion; 2017-2027)

Biospecimen Outlook (Revenue, USD Billion; 2017-2027)

Application Outlook (Revenue, USD Billion; 2017-2027)

End Users Outlook (Revenue, USD Billion; 2017-2027)

BUY NOW (Customized Report Delivered as per Your Specific Requirement)@ https://www.reportsanddata.com/checkout-form/3470

Regional Outlook (Revenue, USD Billion; 2017-2027)

Take a Look at our Related Reports:

Bioprosthetics Market: The increasing prevalence of rheumatoid heart disease, coronary and peripheral artery diseases, and other cardiovascular diseases have led to the increasing demand for long-term treatment and relief, factors that are anticipated to drive bioprosthetics market growth.

Stone Treatment Devices Market: Factors such as mounting geriatric populace, an expansion in the frequencies of stone formation, upsurge in the recurrence of the stone after a medical procedure, a tendency towards minimally invasive procedures are expected to propel the industry in the coming years.

Automated Insulin Delivery Systems Market: Automated Insulin Delivery Systems is an user friendly technology that regulate blood glucose level with the help of continuous glucose monitoring.

Cerebrospinal Fluid (CSF) Management Market: The unique nature of cerebrospinal fluid dynamics in each patient has challenged neurologists, neurosurgeons, and medical device developers. This has led to cumulative demand for advanced cerebral spinal fluid (CSF) management devices.

Sacral Neuromodulation Market: A rise in the prevalence of overactive bladder & urge continence among masses along with the expansion of the geriatric population base across the globe is the key factor driving the market growth.

Central Venous Catheters Market: Catheters are an efficient delivery mechanism for surgical procedures. These are medical devices, which are used for the treatment of a large number of cardiovascular diseases and other chronic disorders.

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help clients make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Reports And Data | Web: http://www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: sales@reportsanddata.com

LinkdIn | Twitter | Blogs

Read the original post:
Biopreservation Market To Reach USD 5.63 Billion By 2027 | Reports and Data - GlobeNewswire

Global Cell Isolation Technology Market Insights, Industry Top Manufactures, Analysis and Forecast 2020 to 2025 – The Market Correspondent

By adminSeptember 10, 2020Stell Cell Research

MarketsandResearch.biz has newly added a new research report titled Global Cell Isolation Technology Market Growth (Status and Outlook) 2020-2025 which is known to provide comprehensive and detailed information about the market for the projected period from 2020 to 2025. The report inspects the crucial data related to the market. The report focuses on different components of the market including market trends, regional outlook, competitive landscape, key players, business approaches. The report determines the global Cell Isolation Technology market growth and market share for the estimated forecast period. The research report has made through several data exploratory techniques which include primary and secondary research.

The reports objective is to show the development in key regions. The global Cell Isolation Technology market is a database mechanism developed for analysis and access to a large volume of unstructured data. The study analyzes market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, player profiles. The research report investigates the whole growth dynamics of the industry as well as market evaluation, manufacturing approach across distinct topologies and competitive landscape analysis.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/59723

Market Segmentation:

The global Cell Isolation Technology market is analyzed for different segments to arrive at an insightful analysis. Such segmentation has been done based on type, application, and region.

The study encompasses profiles of major companies operating in the global market. Key players profiled in the report include: Thermo Fisher Scientific, Inc., Merck, Beckman Coulter, Inc., Terumo BCT, BD Biosciences, Bio-Rad Laboratories, Inc., GE Healthcare, Stemcell Technologies,

The report provides in-depth comprehensive analysis for regional segments that covers Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries) in the global Cell Isolation Technology report with market definitions, classifications, manufacturing processes, cost structures, development policies, and plans.

Market segment by type, the product can be split into: Centrifugation, Flow Cytometry, Cell Electrophoresis,

Market segment by regions/countries, this report covers: Stem cell research, Cancer research, Tissue regeneration, In-vitro diagnostics, Other

Moreover in the report, other data models include vendor positioning grid, market timeline analysis, global Cell Isolation Technology market overview, and guide, company positioning grid, company market share analysis, standards of measurement, top to bottom analysis and vendor share analysis. Market players can effortlessly implement strategies with all the data provided to gain a dominant position and beat the competition in the market.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/59723/global-cell-isolation-technology-market-growth-status-and-outlook-2020-2025

Questions Answered By The Global Cell Isolation Technology Market Report With Regards To The Geographical Spectrum of The Market:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact Us Mark Stone Head of Business Development Phone: +1-201-465-4211 Email: [emailprotected] Web: http://www.marketsandresearch.biz

Joint Pain Injections Market is Thriving Worldwide 2020 | Trends, Growth and Profit Analysis, Forecast by 2027 – The Daily Chronicle

By adminSeptember 10, 2020Platelet Rich Plasma Injections

Sanofi S.A

Joint Pain Injections Market, By Application

Shoulder & Elbow Knee & Ankle Spinal Joints Hip Joint Others

Joint Pain Injections Market, By Type

Steroid Joint Injections Hyaluronic Acid Injections Platelet-rich Plasma (PRP) Injections Placental Tissue Matrix (PTM) Injections Others

Joint Pain Injections Market, By Distribution Channel

Hospital Pharmacies Online Pharmacies Retail Pharmacies

The report provides detailed coverage of the Joint Pain Injections Market, including structure, definitions, applications, and Industry Chain classifications. The Joint Pain Injections Market analysis is provided for the international markets including development trends, competitive landscape analysis, investment plan, business strategy, opportunities and development status of key regions. Development policies and plans are discussed and manufacturing processes and cost structures analyzed. This report also includes information on import / export consumption, supply and demand, costs, industry share, policy, Price, Sales and gross margins.

Ask For Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=39924&utm_source=TDC&utm_medium=001

Joint Pain Injections Market forecast up to 2027, with information such as company profiles, product picture and specification, capacity production, price, cost, revenue, and contact information. Upstream raw materials and equipment as well as downstream demand analyses are also carried out. The Joint Pain Injections Market size, development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed and general research results are offered.

The Joint Pain Injections Market was created on the basis of an in-depth market analysis with contributions from industry experts. The report covers the growth prospects in the coming years and the discussion of the main providers.

To understand how the effects of COVID-19 are addressed in this report. A sample copy of the report is available at https://www.verifiedmarketresearch.com/product/joint-pain-injections-market/?utm_source=TDC&utm_medium=001

Verified Market Researchis a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Mr. Edwyne Fernandes

US: +1 (650)-781-4080 UK: +44 (203)-411-9686 APAC: +91 (902)-863-5784 US Toll-Free: +1 (800)-7821768

Email:[emailprotected]

Continue reading here:
Joint Pain Injections Market is Thriving Worldwide 2020 | Trends, Growth and Profit Analysis, Forecast by 2027 - The Daily Chronicle

Impact of Covid-19 | Retinitis Pigmentosa (Retinitis) Market Report Examines Business Opportunity and Worldwide Scope by Forecast 2020 to 2025 – Galus…

By adminSeptember 10, 2020Gene Therapy Clinics

A new report titled, Global Retinitis Pigmentosa (Retinitis) Market Professional Report 2020-2025 has been added by Garner Insights in its database of research reports. The scope of the report includes a comprehensive study of global, regional, and local markets for different segments of the market.

The study provides complete details about the usage and adoption of Retinitis Pigmentosa (Retinitis) in various industrial applications and geographies. This helps the key stakeholders in knowing about the major development trends, growth strategies, investments, vendor activities, and government initiatives. Moreover, the report specifies the major drivers, restraints, challenges, and lucrative opportunities that are going to impact the growth of the market.

Request Sample Report of Global Retinitis Pigmentosa (Retinitis) Market @https://garnerinsights.com/2015-2025-Global-Retinitis-Pigmentosa-Retinitis-Market-Research-by-Type-End-Use-and-Region-COVID-19-Version#request-sample

Key Players: Sanofi, Amgen, Amarantus Bioscience Holdings, Acucela, Applied Genetic Technologies Corp, Asklepios BioPharmaceutical, Astellas Pharma, Caladrius Biosciences, Dompe Farmaceutici SpA, Dormant Projects, GenSight Biologics SA, Grupo Ferrer Internacional SA, ID Pharma, InFlectis BioScience, Ionis Pharmaceuticals, Mimetogen Pharmaceuticals, Ms Science Corp, Nanovector srl, Novartis AG, Novelion Therapeutics, ProQR Therapeutics, ReNeuron Group Plc, SanBio, Shire (Takeda Pharmaceutical), Spark Therapeutics

Types:

General Treatment Traditional Chinese Medicine Gene Therapy The Surgical Treatment Others

Application:

Hospitals Eye Clinics Others

The report calculates the size of the Global Retinitis Pigmentosa (Retinitis) Market using a bottom-up approach, where data from various end-user industries and its applications across product types were recorded. This data was sourced from the industry experts and company representatives and externally validated through studying historical data of these product types and applications for getting an appropriate size of the Retinitis Pigmentosa (Retinitis) Market. The report conducted secondary research from sources such as company website, news articles, financial reports, press releases, investor presentations, and company annual reports.

Grab Your Report at an Impressive Discount! Please click Here@ https://garnerinsights.com/2015-2025-Global-Retinitis-Pigmentosa-Retinitis-Market-Research-by-Type-End-Use-and-Region-COVID-19-Version#discount

This report forecasts revenue growth at the global, regional, and local levels and provides an analysis of the most recent industry trends from 2020 to 2025 in each of the segments and sub-segments. In addition, the report highlights the impact of COVID-19 on the Global Retinitis Pigmentosa (Retinitis) Market. Some of the major geographies included in the market are given below:

North America (U.S., Canada) Europe (U.K., Germany, France, Italy) Asia Pacific (China, India, Japan, Singapore, Malaysia) Latin America (Brazil, Mexico) Middle East & Africa

The key objectives of the Study: To analyze and forecast the size of the Global Retinitis Pigmentosa (Retinitis) Market in terms of value and volume. To study and provide the market segmentation in detail based on the geography by segmenting the Global Retinitis Pigmentosa (Retinitis) Market into five regions, namely, North America, Europe, Latin America, Asia Pacific, and the Middle East and Africa. To study, identify, and forecast the Global Retinitis Pigmentosa (Retinitis) Market by carrying out SWOT analysis, Porters Five Forces analysis, and Pester analysis. To study the competitive developments such as technological developments, services, and regulative initiatives within the Global Retinitis Pigmentosa (Retinitis) Market. To highlight the impact analysis of the factors affecting the market dynamics such as drivers, restraints, opportunities, and challenges. To strategically profile the leading industry players and thoroughly analyze their overall shares in the market, along with detailing the competitive advantage.

Request customized copy of report @https://garnerinsights.com/2015-2025-Global-Retinitis-Pigmentosa-Retinitis-Market-Research-by-Type-End-Use-and-Region-COVID-19-Version

Continue reading here:
Impact of Covid-19 | Retinitis Pigmentosa (Retinitis) Market Report Examines Business Opportunity and Worldwide Scope by Forecast 2020 to 2025 - Galus...

Hemophilia Treatment Market: Trends, Applications, Industry Competitive Analysis, Growth,Forecast: 2019 to 2029 – The News Brok

By adminSeptember 10, 2020Gene Therapy Clinics

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Hemophilia Treatment market.

Trusted Business Insights presents an updated and Latest Study on Hemophilia Treatment Market 2019-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Hemophilia Treatment market during the forecast period (2019-2029). It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Hemophilia Treatment Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Abstract, Snapshot, Market Analysis & Market Definition: Hemophilia Treatment Market Industry / Sector Trends

Hemophilia Treatment Market size was valued USD 10.5 billion in 2018 and is expected to witness 5.0% CAGR from 2019 to 2025.

U.S. hemophilia treatment market, by disease, 2018 & 2025 (USD Million)

Growing prevalence of hemophilia across the globe will be one of the major market augmenting factors over the forthcoming years. As per the recent statistics published by Centers for Disease Control and Prevention (CDC), hemophilia A affects around 1 in 5,000 live male births in the U.S. Majority of the people with hemophilia are diagnosed at a young age. According to the CDC data, average age of hemophilia diagnosis in the U.S. is 36 months for mild hemophilia, 8 months for moderate hemophilia and 1 month for severe hemophilia. Hence, rise in number of people suffering from hemophilia will enhance the hemophilia treatment market growth in the near future.

Rise in several government initiatives will augment the industry growth over the projection period. Organization including the World Hemophilia Organization along with governments of several countries carry out awareness and diagnosis programs. Government efforts to enhance public health and treat underprivileged people will result in boosting the hemophilia treatment market growth in the near future.

However, high cost of hemophilia medications will be one the major growth impeding factors. High investment, R&D, manufacturing and marketing of drugs by manufacturers is the reason for high cost of the products. High cost of products are unaffordable for the middle and lower income class families, thus resulting in restraining the business growth.

Market Segmentation, Outlook & Regional Insights: Hemophilia Treatment Market

Hemophilia Treatment Market, By Disease

Germany hemophilia treatment market share, by disease, 2018

Hemophilia A treatment market was valued at USD 6,743.7 million in the year 2018. Hemophilia A is a common blood disorder and the prevalence rate is high in developing and underdeveloped regions. As per the recent statistics, around 19,000 people in India suffer from hemophilia and only 15% of the patients are registered. Increase in number of people suffering from hemophilia A and rise in awareness among the people regarding the treatment and medications of hemophilia will result in rise in demand and adoption rate of hemophilia drugs, fueling the business growth.

Hemophilia B treatment market is estimated to grow at 4.0% over the estimation period. As per a recent research article, the prevalence of hemophilia B is quite rare as compared to hemophilia A and the incidence of hemophilia B is around 1 in 30,000 in the U.S. Recent technological advancements has led to growing medications for hemophilia B treatment, hence resulting in boosting the segmental growth.

Hemophilia Treatment Market, By Product

Recombinant factor concentrates market was valued at USD 6,626.9 million in the year 2018. Rise in production of recombinant factor concentrates has provided growth opportunity to treat hemophilia and overcome limited availability of plasma-derived concentrates. Also, increased safety of replacement therapy with the help of recombinant factor concentrates has dramatically enhanced the quality of patient life. Increase in preference of recombinant factor concentrates in treatment of hemophilia will ultimately lead to augmenting the business growth over the forecast period.

Extended half-life products market is estimated to witness a robust growth of 5.3% over the forecast period. Recent research and development has led to the production of new factor concentrates that are efficient and need less frequent injections. The reason for fewer injections are due to the increased half-life of the product. Hence, recent technological advancements and new product launches will lead to increase in demand and adoption rate of extended half-life products, thereby fueling the business growth.

Hemophilia Treatment Market, By Patient

Hemophilia treatment in adults was valued at USD 6,778.1 million in the year 2018. As per a recent research article, around 65% of the people suffering from hemophilia are adults. In some of the adults mild hemophilia is diagnosed in the later stages of life. As the age of patients increases, the need for hemophilia care also increases. There are various possibilities of developing moderate to severe hemophilia in adults. Hence, growing age results in rise in chances of developing hemophilia in adults, thereby boosting the demand for hemophilia treatment in the near future.

Hemophilia treatment in pediatrics is projected to grow at 5.2% over the estimation period. Hemophilia is inherited diseases that are passed to children from gene located on X-chromosome. In approximately one third of children, no family history of hemophilia is found, and the disease occurs due to gene mutation. Children with hemophilia gene bruise easily, bleed more with surgeries and have frequent nose bleedings. According to the National Center for Biotechnology Information, severe form of factor deficiencies including hepatitis A and hepatitis B were diagnosed in the neonates with 52% and 68% of cases respectively. Hence, increase in prevalence of hemophilia in children will augment the hemophilia treatment market growth in the near future.

Hemophilia Treatment Market, By Treatment

Prophylaxis treatment market was valued at USD 7,219.9 million in the year 2018. Long-term prophylaxis treatment is considered as standard of care to prevent chronic arthropathy and joint bleeding in patients with severe hemophilia. As per a recent research, it was observed that the prophylaxis treatment for hemophilia was quite effective and slowed the progression of joint damage. Majority of patients and healthcare providers opt for prophylaxis treatment owing to its efficiency and better end results. Hence, increase in preference of prophylaxis treatment will further augment the business growth in the near future.

On demand treatment market is estimated to grow at 5.2% over the forthcoming years. People suffering from mild to moderate hemophilia are treated with on demand treatment to prevent bleeding. Children with severe hemophilia initially receive prophylactic therapy to prevent bleeding; however, after reaching adulthood, they switch to on-demand treatment for several reasons, such as strict work schedules, inconvenience of visiting doctors or going to a clinic several times a week, along with high expenditure related to continuous prophylactic therapy. Hence, the aforementioned reasons will be responsible for the market growth of on demand treatment segment.

Hemophilia Treatment Market, By Therapy

Factor replacement therapy market was valued at USD 9,574.2 million in the year 2018. As per the Medical and Scientific Advisory Council (MASAC) of National Hemophilia Foundation (NHF), the use of recombinant factor concentrates in children is quite effective as the recombinant factor does not contain actual human blood and cannot transmit harmful viruses including hepatitis. Hence, the use of factor replacement therapy is quite common due to direct infusion of clotting factors, resulting in boosting the segmental growth.

Non-factor replacement therapy is projected to show rapid growth of 38.3% over the estimation period. One of the challenging problems in the treatment of hemophilia is the development of alloantibodies against the infused factor concentrates. Development of inhibitors render the factor replacement therapy ineffective, leading to high risk of morbidity and mortality in patients. Also, there is growing interest in non-factor replacement therapy agents that act by inhibiting anticoagulant pathways or enhancing coagulation. Hence, introduction of new therapeutic agents in hemophilia treatment will enhance the business growth.

Hemophilia Treatment Market, By Drug Class

Coagulation factors market was valued at USD 9,948.3 million in the year 2018. Hemophilia is considered as hereditary blood disease with coagulation time. The use of coagulation factors is quite common and is used mostly in the replacement therapy. Absence or improper functioning of several clotting factors in the blood such as factors VIII, XI, etc. result in causing hemophilia. Hence, use of several clotting factors to replace the absent blood clotting factors will lead to boosting the hemophilia treatment market growth.

Vasopressin drug class market is estimated to grow at 6.0% in the near future. Patients suffering from mild hemophilia use vasopressin drugs for joint and muscle bleeds, bleeding in mucous membranes of nose and mouth and pre and post-surgery. Vasopressin drugs comes in injectable and nasal spray form and is comparatively easy to use. Hence, the aforementioned factors will be responsible for the market growth of vasopressin drug class.

Hemophilia Treatment Market, By Route of Administration

Injectable route of administration for hemophilia treatment was valued at USD 9,629.3 million in the year 2018. Majority of the drugs and factor concentrate products are intravenously given to patients for better and quick results. Intravenous route of administration helps the medications to directly interact with the blood. Hence, majority of healthcare providers opt for injectable or intravenous route of drug administration to treat hemophilia for better and quick results, hence boosting the market growth.

Nasal spray or intra nasal route of administration will grow at 6.0% over the forecast period. Drugs including vasopressin are required to be taken by patients for joint and muscle bleeds, and bleeding in mucous membranes of nose and mouth. Several advantages offered by nasal spray such as ease of use and user convenience will result in growing demand, thereby fueling the business growth.

Hemophilia Treatment Market, By End-use

Hemophilia treatment centers as end-use was valued at USD 4,134.6 million in the year 2018. A substantial proportion of hemophilia treatment is carried out in such centers. During the forecast period, the hemophilia treatment center end-use market segment will continue to lead, owing to rising number of special care provided and peoples increased preference for these centers over other healthcare settings.

Clinics as end-use is estimated to grow at 5.3% in the near future. Clinics provide fast-track treatment and infusion of factor concentrates to patients. Also, immediate and short-time treatment provided during the daytime to people with busy and hectic work schedule will enhance business growth in the near future.

Hemophilia treatment Market, By Region

Europe hemophilia treatment market, by country, 2025 (USD Million)

U.S. dominated the North America hemophilia treatment market and was valued at USD 3,539.3 million in the year 2018. As per the Hemophilia Federation of America, hemophilia A affects around 1 in 5,000 people in the U.S. and approximately 400 new-borns are diagnosed with hemophilia every year. Also, presence of favorable reimbursement and insurance in the country will result in growing demand and adoption rate of hemophilia medications, expanding the hemophilia treatment market growth in the country.

India hemophilia treatment market is projected to grow at 9.2% over the estimation period. Various government initiatives has helped in building necessary infrastructure, empower healthcare providers and patients to self-administer treatment at home, hence helping patients achieve a better quality of life. Recent technological advancements, rise in awareness among people, new product launches and government initiatives will augment the business growth over the forecast period.

Key Players, Recent Developments & Sector Viewpoints: Hemophilia Treatment Market

Major industry players involved in the hemophilia treatment market include Swedish Orphan Biovitrum AB, Sanofi SA, Pfizer, Novo Nordisk, Genentech, CSL Behring, Biogen, among other market players. These players have implemented several strategic initiatives such as collaborations, merger and acquisitions, new product launches and partnerships that have enhanced their financial stability, helped them evolve as major industrial players and gain strong market position.

Hemophilia Treatment Industry Viewpoint

Hemophilia has been an extremely old and critical disease that the global population has been facing. People in ancient times have written and articulated about bleeding problems. Some of the bleeding problems identified have been different as compared to others. But little they knew about blood clots and the disease caused by their deficiency. Until before World War II, doctors learned about hemophilia A and its cause due to deficiency of factor VIII. Several other blood factors were recognized later on and Roman numeral names were given to avoid confusion. Hemophilia research has come a long way with scientists discovering human blood in different groups, hence helping blood transfusions to be more successful. In 1960s, Dr. Judith Pool discovered a procedure to freeze and thaw plasma to get a layer of factor-rich plasma called as cryoprecipitate. Use of cryoprecipitate was the best way of stopping hemophilia bleeding. Later on, the greatest breakthrough that came in hemophilia treatment was the development and introduction of factor concentrates. These clotting factors can be freeze-dried to a powder that can be easily stored and consumed. With the help of these factor concentrates, people suffering from hemophilia can be treated quickly with maximum efficiency. Also, factor concentrates have helped people treat their bleedings at home or at work, resulting in people to lead normal lives. Also, development and introduction of new medications and technologies such as non-factor replacement therapy, extended half-life products, gene therapy, etc. will augment the growth of hemophilia treatment market growth in the near future.

Key Insights Covered: Exhaustive Hemophilia Treatment Market 1. Market size (sales, revenue and growth rate) of Hemophilia Treatment industry. 2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Hemophilia Treatment industry. 3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Hemophilia Treatment industry. 4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Hemophilia Treatment industry.

Research Methodology: Hemophilia Treatment Market

Looking for more? Check out our repository for all available reports on Hemophilia Treatment in related sectors.

Quick Read Table of Contents of this Report @ Hemophilia Treatment Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Trusted Business Insights Shelly Arnold Media & Marketing Executive Email Me For Any Clarifications Connect on LinkedIn Click to follow Trusted Business Insights LinkedIn for Market Data and Updates. US: +1 646 568 9797 UK: +44 330 808 0580

See the article here:
Hemophilia Treatment Market: Trends, Applications, Industry Competitive Analysis, Growth,Forecast: 2019 to 2029 - The News Brok

Study Identifies New Set of Genes That May Explain Why People with Down Syndrome Have a Higher Risk of Leukemia – DocWire News

By adminSeptember 10, 2020Induced Pluripotent Stem Cells

A study which appeared in the journal Oncotarget sheds light on why people with Down syndrome are at higher risk of Leukemia. Researchers pinpointed a new set of genes overexpressed in endothelial cells of individuals with Down syndrome, thus creating an environment conducive for leukemia.

Down syndrome occurs in approximately in one in 700 babies, and individuals with the syndrome not only development physical impairments, they have a greatly augmented risk of developing leukemia. Specifically, people with Down syndrome have a 500-fold risk of developing acute megakaryoblastic leukemia (AMKL) and a 20-fold risk of being diagnosed with acute lymphoblastic leukemia (ALL).

In this study, researchers used skin samples from patients with Down syndrome to create induced pluripotent stem cells (iPSC). They subsequently differentiated the iPSC cells into that were then endothelial cells. The researchers observed that the endothelial cell genetic expression produced altered endothelial function throughout cell maturation. We found that Down syndrome, or Trisomy 21, has genome-wide implications that place these individuals at higher risk for leukemia, says co-lead author Mariana Perepitchka, BA, Research Associate at the Manne Research Institute at Lurie Childrens via a press release. We discovered an increased expression of leukemia-promoting genes and decreased expression of genes involved in reducing inflammation. These genes were not located on chromosome 21, which makes them potential therapeutic targets for leukemia even for people without Down syndrome.

Our discovery of leukemia-conducive gene expression in endothelial cells could open new avenues for cancer research, said co-lead author Yekaterina Galat, BS, Research Associate at the Manne Research Institute at Lurie Childrens.

Fortunately, advances in iPSC technology have provided us with an opportunity to study cell types, such as endothelial cells, that are not easily attainable from patients, stated senior author Vasil Galat, PhD, Director of Human iPS and Stem Cell Core at Manne Research Institute at Lurie Childrens and Research Assistant Professor of Pathology at Northwestern University Feinberg School of Medicine. If our results are confirmed, we may have new gene targets for developing novel leukemia treatments and prevention.

Go here to see the original:
Study Identifies New Set of Genes That May Explain Why People with Down Syndrome Have a Higher Risk of Leukemia - DocWire News